NO135994B - - Google Patents
Download PDFInfo
- Publication number
- NO135994B NO135994B NO2778/71A NO277871A NO135994B NO 135994 B NO135994 B NO 135994B NO 2778/71 A NO2778/71 A NO 2778/71A NO 277871 A NO277871 A NO 277871A NO 135994 B NO135994 B NO 135994B
- Authority
- NO
- Norway
- Prior art keywords
- virus
- rubella
- cells
- culture
- passages
- Prior art date
Links
- 241000710799 Rubella virus Species 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 14
- 210000003292 kidney cell Anatomy 0.000 claims description 13
- 241000700198 Cavia Species 0.000 claims description 9
- 241000700605 Viruses Species 0.000 description 57
- 229960005486 vaccine Drugs 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 32
- 201000005404 rubella Diseases 0.000 description 31
- 238000004113 cell culture Methods 0.000 description 27
- 239000007788 liquid Substances 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 21
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 12
- 230000002238 attenuated effect Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000003113 dilution method Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000003800 pharynx Anatomy 0.000 description 6
- 230000003313 weakening effect Effects 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 239000012531 culture fluid Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 102000004407 Lactalbumin Human genes 0.000 description 4
- 108090000942 Lactalbumin Proteins 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- 241000172803 Rubella virus strain TO-336 Species 0.000 description 3
- 229940124968 Rubella virus vaccine Drugs 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 1
- 241000709714 Echovirus E11 Species 0.000 description 1
- 241000409349 Erythranthe rubella Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002222 dihydrostreptomycin Drugs 0.000 description 1
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960003131 rubella vaccine Drugs 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/20—Rubella virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36211—Rubivirus, e.g. rubella virus
- C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP45086789A JPS4838843B1 (nl) | 1970-10-03 | 1970-10-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO135994B true NO135994B (nl) | 1977-03-28 |
| NO135994C NO135994C (nl) | 1977-07-06 |
Family
ID=13896515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2778/71A NO135994C (nl) | 1970-10-03 | 1971-07-21 |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS4838843B1 (nl) |
| BE (1) | BE769644A (nl) |
| CH (1) | CH581195A5 (nl) |
| DE (1) | DE2132911C2 (nl) |
| DK (1) | DK128789B (nl) |
| FR (1) | FR2112249B1 (nl) |
| GB (1) | GB1360838A (nl) |
| NL (1) | NL171777C (nl) |
| NO (1) | NO135994C (nl) |
| SE (1) | SE377279B (nl) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE279038C (nl) * |
-
1970
- 1970-10-03 JP JP45086789A patent/JPS4838843B1/ja active Pending
-
1971
- 1971-06-24 NL NLAANVRAGE7108753,A patent/NL171777C/nl not_active IP Right Cessation
- 1971-06-24 SE SE7108282A patent/SE377279B/xx unknown
- 1971-07-02 DE DE2132911A patent/DE2132911C2/de not_active Expired
- 1971-07-05 FR FR7124518A patent/FR2112249B1/fr not_active Expired
- 1971-07-07 BE BE769644A patent/BE769644A/xx not_active IP Right Cessation
- 1971-07-13 DK DK345271AA patent/DK128789B/da unknown
- 1971-07-21 NO NO2778/71A patent/NO135994C/no unknown
- 1971-07-22 GB GB3443571A patent/GB1360838A/en not_active Expired
- 1971-07-23 CH CH1090071A patent/CH581195A5/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS4838843B1 (nl) | 1973-11-20 |
| NL171777C (nl) | 1983-05-16 |
| FR2112249B1 (nl) | 1975-04-18 |
| SE377279B (nl) | 1975-06-30 |
| NO135994C (nl) | 1977-07-06 |
| BE769644A (fr) | 1972-01-07 |
| NL7108753A (nl) | 1972-04-05 |
| GB1360838A (en) | 1974-07-24 |
| NL171777B (nl) | 1982-12-16 |
| FR2112249A1 (nl) | 1972-06-16 |
| DE2132911A1 (de) | 1972-04-06 |
| DK128789B (da) | 1974-07-01 |
| CH581195A5 (nl) | 1976-10-29 |
| DE2132911C2 (de) | 1984-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sever et al. | Rubella virus. | |
| Elek et al. | Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero | |
| Liess et al. | Studies on transplacental transmissibility of a Bovine Virus Diarrhoea (BVD) vaccine virus in cattle 1: II. Inoculation of pregnant cows without detectable neutralizing antibodies to BVD virus 90–229 days before parturition (51st to 190th day of gestation) | |
| Beare et al. | Investigation into the attenuation of influenza viruses by serial passage | |
| Haesebrouck et al. | Effect of intratracheal challenge of fattening pigs previously immunised with an inactivated influenza H1N1 vaccine | |
| Stokes Jr et al. | Live attenuated mumps virus vaccine. II. Early clinical studies | |
| SHISHIDO et al. | Development of attenuated rubella virus vaccines in Japan | |
| EP0030063A2 (en) | Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines, process for preventing infectious bronchitis and infectious-bronchitis virus strains | |
| Bussell et al. | Canine distemper virus in ferret, dog and bovine kidney cell cultures | |
| Scott et al. | Cell‐mediated immunity in respiratory syncytial virus disease | |
| Dolgin et al. | Immunizing properties of live attenuated measles virus | |
| Gallagher et al. | Cell-mediated immune responsiveness to measles: its occurrence as a result of naturally acquired or vaccine-induced infection and in infants of immune mothers | |
| Parkman et al. | Rubella virus: Isolation, characterization, and laboratory diagnosis | |
| Cabasso et al. | A bivalent live virus vaccine against canine distemper (CD) and infectious canine hepatitis (ICH). | |
| Musser et al. | Measles virus growth in canine renal cell cultures | |
| CS199569B2 (en) | Method of producing vaccine against influenza | |
| Schwarz et al. | Propagation of measles virus in non-primate tissue culture. I. Propagation in bovine kidney tissue culture | |
| Plotkin et al. | Persistence of antibodies after vaccination with living attenuated poliovirus | |
| Miller et al. | Reactions of human sera to avian adenoviruses and Newcastle disease virus | |
| Buynak et al. | Jeryl Lynn Strain Live Attenuated Mumps Virus Vaccine: Influence of Age, Virus Dose, Lot, and γGlobulin Administration on Response | |
| FUKUMI et al. | Studies on the adenovirus as an etiological agent of pharyngoconjunctival fever | |
| Hyslop et al. | Antigenic differences between strains of foot-and-mouth disease virus of type SAT 1 | |
| NO135994B (nl) | ||
| US3098011A (en) | Process of producing a vaccine against distemper | |
| CA1286226C (en) | Vaccine against mumps and process for its preparation |